发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Erratum: Bariatric surgery and medicines [Correction]. 更正:减肥手术和药物[更正]。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.074
{"title":"Erratum: Bariatric surgery and medicines [Correction].","authors":"","doi":"10.18773/austprescr.2022.074","DOIUrl":"https://doi.org/10.18773/austprescr.2022.074","url":null,"abstract":"<p><p>[This corrects the article on p. 162 in vol. 45, PMID: 36382169.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/65/austprescr-45-219.PMC9722356.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mecasermin for primary insulin-like growth factor-1 deficiency. Mecasermin治疗原发性胰岛素样生长因子-1缺乏。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.077
{"title":"Mecasermin for primary insulin-like growth factor-1 deficiency.","authors":"","doi":"10.18773/austprescr.2022.077","DOIUrl":"https://doi.org/10.18773/austprescr.2022.077","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/a7/austprescr-45-215.PMC9722352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wither Australian Prescriber? 枯萎澳大利亚处方?
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.076
John Dowden
{"title":"Wither <i>Australian Prescriber</i>?","authors":"John Dowden","doi":"10.18773/austprescr.2022.076","DOIUrl":"https://doi.org/10.18773/austprescr.2022.076","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/2e/austprescr-45-210.PMC9722344.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pemigatinib for cholangiocarcinoma. Pemigatinib治疗胆管癌。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.078
{"title":"Pemigatinib for cholangiocarcinoma.","authors":"","doi":"10.18773/austprescr.2022.078","DOIUrl":"https://doi.org/10.18773/austprescr.2022.078","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/b6/austprescr-45-216.PMC9722347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selinexor for multiple myeloma. Selinexor治疗多发性骨髓瘤。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.072
{"title":"Selinexor for multiple myeloma.","authors":"","doi":"10.18773/austprescr.2022.072","DOIUrl":"https://doi.org/10.18773/austprescr.2022.072","url":null,"abstract":"Exportin-1 is an essential nuclear exporter of many tumour suppressor proteins, growth regulator proteins and several classes of messenger RNAs, including those of oncogenic proteins. It is overexpressed in several cancers including multiple myeloma. Selinexor is a selective inhibitor of exportin-1. This inhibition leads to marked accumulation of the tumour suppressor proteins and growth regulator proteins in the nucleus and reduced expression of several oncoproteins, resulting in cell cycle arrest and apoptosis of cancer cells.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/39/austprescr-45-217.PMC9722349.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes. 地西他滨/cedazuridine治疗慢性髓单核细胞白血病，骨髓增生异常综合征。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.071
{"title":"Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes.","authors":"","doi":"10.18773/austprescr.2022.071","DOIUrl":"https://doi.org/10.18773/austprescr.2022.071","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/b8/austprescr-45-213.PMC9722354.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10722531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elasomeran/imelasomeran for prevention of COVID-19. 用于预防新冠肺炎的Elasomeran/imelasomeran。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.073
{"title":"Elasomeran/imelasomeran for prevention of COVID-19.","authors":"","doi":"10.18773/austprescr.2022.073","DOIUrl":"https://doi.org/10.18773/austprescr.2022.073","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/af/austprescr-45-214.PMC9722357.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteonecrosis of the jaw and denosumab. 颌骨骨坏死和地诺单抗。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.066
Alastair N Goss
{"title":"Osteonecrosis of the jaw and denosumab.","authors":"Alastair N Goss","doi":"10.18773/austprescr.2022.066","DOIUrl":"https://doi.org/10.18773/austprescr.2022.066","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/3e/austprescr-45-208.PMC9722355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10433277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The end of NPS MedicineWise. NPS MedicineWise的终结。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.075
Deborah Rigby
{"title":"The end of NPS MedicineWise.","authors":"Deborah Rigby","doi":"10.18773/austprescr.2022.075","DOIUrl":"https://doi.org/10.18773/austprescr.2022.075","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/25/austprescr-45-186.PMC9722346.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diuretics in the management of chronic heart failure: when and how. 利尿剂在慢性心力衰竭治疗中的应用:时间和方式。
IF 2.7
Australian Prescriber Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.069
Joseph S Magdy, James McVeigh, Praveen Indraratna
{"title":"Diuretics in the management of chronic heart failure: when and how.","authors":"Joseph S Magdy,&nbsp;James McVeigh,&nbsp;Praveen Indraratna","doi":"10.18773/austprescr.2022.069","DOIUrl":"https://doi.org/10.18773/austprescr.2022.069","url":null,"abstract":"<p><p>Heart failure is an increasingly prevalent condition resulting in recurrent hospitalisations and significant mortality and morbidity. The management of heart failure has evolved, and multiple drugs have an established mortality benefit in heart failure with reduced ejection fraction. Although the focus should be on ensuring that patients are treated with the maximum tolerated doses of these guideline-directed therapies, diuretics continue to play a key role in the management of clinical congestion in all forms of heart failure. Clinicians play a key role in heart failure management. Familiarity with the role of diuretics and their dosing and monitoring is critical.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/1e/austprescr-45-200.PMC9722345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信